These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19895637)

  • 1. Mid- and high-ratio premix insulin analogues: potential treatment options for patients with type 2 diabetes in need of greater postprandial blood glucose control.
    Christiansen JS; Liebl A; Davidson JA; Ligthelm RJ; Halimi S
    Diabetes Obes Metab; 2010 Feb; 12(2):105-14. PubMed ID: 19895637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Premixed insulin treatment for type 2 diabetes: analogue or human?
    Garber AJ; Ligthelm R; Christiansen JS; Liebl A
    Diabetes Obes Metab; 2007 Sep; 9(5):630-9. PubMed ID: 17697056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin therapy in type 2 diabetes: what is the evidence?
    van Avendonk MJ; Rutten GE
    Diabetes Obes Metab; 2009 May; 11(5):415-32. PubMed ID: 19175375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study.
    Fritsche A; Larbig M; Owens D; Häring HU;
    Diabetes Obes Metab; 2010 Feb; 12(2):115-23. PubMed ID: 20092584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.
    Rolla AR; Rakel RE
    Clin Ther; 2005 Aug; 27(8):1113-25. PubMed ID: 16199240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
    Giugliano D; Ceriello A; Razzoli E; Esposito K
    Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes.
    Clements MR; Tits J; Kinsley BT; Råstam J; Friberg HH; Ligthelm RJ
    Diabetes Obes Metab; 2008 Mar; 10(3):229-37. PubMed ID: 18269638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control in type 2 diabetes mellitus patients undergoing major surgery: comparison of three subcutaneous insulin regimens.
    Mathur SK; Bansal A; Khan ZY
    J Indian Med Assoc; 2009 Nov; 107(11):759-61. PubMed ID: 20469779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of human and analogue insulin trials.
    Gough SC
    Diabetes Res Clin Pract; 2007 Jul; 77(1):1-15. PubMed ID: 17112621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An exploratory study of the effect of using high-mix biphasic insulin aspart in people with type 2 diabetes.
    Dashora U; Ashwell SG; Home PD
    Diabetes Obes Metab; 2009 Jul; 11(7):680-7. PubMed ID: 19527481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Designer insulins regimens in clinical practice--pilot multicenter Indian study.
    Joshi SR; Kalra S; Badgandi M; Rao YS; Chawla M
    J Assoc Physicians India; 2005 Sep; 53():775-9. PubMed ID: 16334621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations.
    Evans M; Schumm-Draeger PM; Vora J; King AB
    Diabetes Obes Metab; 2011 Aug; 13(8):677-84. PubMed ID: 21410860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rapid-acting insulin analogs on overall glycemic control in type 1 and type 2 diabetes mellitus.
    Ristic S; Bates PC
    Diabetes Technol Ther; 2003; 5(1):57-66. PubMed ID: 12725708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of the co-formulation of insulin degludec and insulin aspart.
    Kumar A; Awata T; Bain SC; Ceriello A; Fulcher GR; Unnikrishnan AG; Arechavaleta R; Gonzalez-Gálvez G; Hirose T; Home PD; Kaku K; Litwak L; Madsbad S; Pinget M; Mehta R; Mithal A; Tambascia M; Tibaldi J; Christiansen JS
    Int J Clin Pract; 2016 Aug; 70(8):657-67. PubMed ID: 27384031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin therapy for type 2 diabetes: premixed or basal-prandial?
    Halbron M; Jacqueminet S; Sachon C; Bosquet F; Hartemann-Heurtier A; Grimaldi A
    Diabetes Metab; 2007 Sep; 33(4):316-20. PubMed ID: 17466560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.
    Lankisch MR; Ferlinz KC; Leahy JL; Scherbaum WA;
    Diabetes Obes Metab; 2008 Dec; 10(12):1178-85. PubMed ID: 19040645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refining basal insulin therapy: what have we learned in the age of analogues?
    Devries JH; Nattrass M; Pieber TR
    Diabetes Metab Res Rev; 2007 Sep; 23(6):441-54. PubMed ID: 17668418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for insulin therapy in type 2 diabetes.
    Edelman SV; Morello CM
    South Med J; 2005 Mar; 98(3):363-71. PubMed ID: 15813164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.